Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 5/20 | 0.67 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.67 |
| ▸ | SSTR2 | P30874 | 4/20 | 0.67 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.67 |
| ▸ | SSTR3 | P32745 | 4/20 | 0.67 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.47 |
| ▸ | GJB2 | P29033 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772244 | 1.00 | SSTR5 (0.67) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL6879922 | 0.99 | SSTR5 (0.65) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL6879920 | 0.99 | SSTR5 (0.65) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL8152898 | 0.94 | SSTR5 (0.60) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL8152902 | 0.94 | SSTR5 (0.60) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL6383598 | 0.94 | SSTR5 (0.64) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL6893382 | 0.92 | SSTR5 (0.59) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL24122546 | 0.90 | SSTR1 (0.72) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL6298172 | 0.90 | SSTR1 (0.72) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL7148930 | 0.90 | SSTR1 (0.72) | SSTR5SSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168179-B2 | Macromolecular transition metal complexes for treatment of cancer and process for their preparation | FACULDADE DE CIÉNCIAS DA UNIVERSIDADE DE LISBOA (PT) | 2021-11-09 | — | — | US | disclosed |
| EP-3227307-B1 | MACROMOLECULAR TRANSITION METAL COMPLEXES FOR TREATMENT OF CANCER AND PROCESS FOR THEIR PREPARATION | FACULDADE DE CIENCIAS DA UNIV DE LISBOA (PT) | 2020-10-21 | — | — | EP | disclosed |
| US-20180009940-A1 | MACROMOLECULAR TRANSITION METAL COMPLEXES FOR TREATMENT OF CANCERAND PROCESS FOR THEIR PREPARATION | FACULDADE DE CIÉNCIAS DA UNIVERSIDADE DE LISBOA (PT) | 2018-01-11 | — | — | US | disclosed |
| WO-2010073126-A2 | COMPOUNDS USEFUL IN DELIVERING ANTI-NEOPLASTIC THERAPY AND DIAGNOSTIC IMAGING TO HYPOXIC CELLS AND METHODS OF USE THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2010-07-01 | — | — | WO | disclosed |
| US-20090275524-A1 | NOVEL HYPOCHOLESTEROLEMIC COMPOUNDS | LIPIDEON BIOTECHNOLOGY AG | 2009-11-05 | — | — | US | disclosed |
| US-7544667-B2 | Hypocholesterolemic compounds | LIPIDEON BIOTECHNOLOGY AG (CH) | 2009-06-09 | — | — | US | disclosed |
| US-20080167255-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | MICROBIA, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1885694-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | Microbia, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7320972-B2 | 4-Biarylyl-1-phenylazetidin-2-ones | MICROBIA, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070275909-A1 | Useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels; carbohydrate-containing pyrazolidinone or oxazolidinone derivatives, for example | LIPIDEON BIOTECHNOLOGY AG (CH) | 2007-11-29 | — | — | US | disclosed |
| US-5097023-A | α-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-03-17 | — | — | US | disclosed |
| WO-1991018915-A1 | NOVEL α-GLUCOSIDASE INHIBITORS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-12-12 | — | — | WO | disclosed |
| EP-0422975-A1 | Alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-17 | — | — | EP | disclosed |
| EP-0422307-A1 | Novel alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-17 | — | — | EP | disclosed |
| EP-0389723-A1 | Novel alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| EP-0390674-A1 | Novel alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| EP-0344383-A1 | Novel alpha-Glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-12-06 | — | — | EP | disclosed |
| EP-0345104-A2 | Novel Alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-12-06 | — | — | EP | disclosed |
| US-4801710-A | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO., INC. (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0184473-A1 | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO. INC. (US) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167255-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | APOB, CYP46A1, PCSK9 | SSTR5 4191/4885SSTR1 4669/4885SSTR2 4097/4885 |
| US-20180009940-A1 | MACROMOLECULAR TRANSITION METAL COMPLEXES FOR TREATMENT OF CANCERAND PROCESS FOR THEIR PREPARATION | MDH1, SLC11A2, EXOSC9 | SSTR5 2621/4885SSTR1 3914/4885SSTR2 3619/4885 |
| US-11168179-B2 | Macromolecular transition metal complexes for treatment of cancer and process for their preparation | ABCB7, TFRC, IMMT | SSTR5 2678/4885SSTR1 3655/4885SSTR2 3583/4885 |
| US-20090275524-A1 | NOVEL HYPOCHOLESTEROLEMIC COMPOUNDS | CYP46A1, SREBF1, CETP | SSTR5 1865/4885SSTR1 3275/4885SSTR2 2571/4885 |
| US-20070275909-A1 | Useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels; carbohydrate-containing pyrazolidinone or oxazolidinone derivatives, for example | PCSK9, APOB, HMGCR | SSTR5 1360/4885SSTR1 3011/4885SSTR2 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.